Research Associate

Telephone: +44 01223 761944

Email: ld429@medschl.cam.ac.uk

ORCiD  – 0000-0003-1214-8080

Background

Education:
B.Sc. Joint Honours in Mathematics and Psychology at the University of Newcastle (graduated 2011)
M.Sc. Medical Statistics at the London School of Hygiene and Tropical Medicine (graduated 2012)
Ph.D. Genetic Epidemiology (completed 2016)
Research positions:
Research Assistant/Statistician, Department of Oncology, University of Cambridge (2012-2013)
Genetic Epidemiologist/Statistician, Centre for Cancer Genetic Epidemiology, University of Cambridge (2016-)

Research

Genetic epidemiology of response to cancer treatment
Genome-wide association studies and next-generation sequencing studies of chemotherapy and radiotherapy toxicity
Next generation sequencing studies of breast cancer susceptibility

Selected Publications

SL Kerns, L Dorling, L Fachal, et al. Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. EBioMedicine (accepted 2016)

M Ahmed, L Dorling, S Kerns, et al. Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. British journal of cancer (accepted 2016)

L Dorling, S Kar, K Michailidou, et al (2016). The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity: a case-control study. PLoS One 11 (7), e0158984

L Dorling, GC Barnett, K Michailidou, et al (2016). Patients with a high polygenic risk of breast cancer do not have an increased risk of radiotherapy toxicity. Clinical Cancer Research 22 (6), 1413-1420

JE Abraham, L Hiller, L Dorling, et al (2015). A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC medicine 13 (1), 1